Project Description

Oral Abstract Presentation
Selected by the 2020 Annual Meeting Scientific Program Committee
Type: Oral Abstract Presentation
Presenter: Ticiana Leal, MD
Presented: May 29, 2020
Abstract ref: 9000
Subtitles/Captions:

Authors: Ticiana Leal, Yating Wang, Afshin Dowlati, DeQuincy Andrew Lewis, Yuanbin Chen, Amit Ramesh Mohindra, Mohammad Razaq, Harish G. Ahuja, Jijun Liu, David M. King, Christopher Joseph Sumey, Suresh S. Ramalingam; University of Wisconsin Carbone Cancer Center, Madison, WI; ECOG-ACRIN Biostatistics Center, Boston, MA; Case Western Reserve University and University Hospitals Case Medical Center, Cleveland, OH; Randolph Cancer Ctr, Asheboro, NC; Cancer and Hematology Centers of Western Michigan, Grand Rapids, MI; Ramesh K Mohindra MD PC, Franklin, MI; University of Oklahoma Health Sciences Center, Oklahoma City, OK; Aspirus Reg Cancer Ctr, Wausau, WI; Illinois Cancer Care, Peoria, IL; Minnesota Onc, St Paul, MN; Univ of Colorado, Aurora, CO; Winship Cancer Institute, Emory University Hospital, Atlanta, GA

Abstract Disclosures

Research Funding: ECOG-ACRIN

Background: Immune checkpoint inhibition is now given in combination with chemotherapy for first line (1L) therapy of extensive stage small cell lung cancer (ES-SCLC). We conducted a randomized phase II study of nivolumab (anti-PD1) in combination with platinum-etoposide (CE) as 1L treatment for patients with ES-SCLC (EA5161, NCT03382561).

Methods: Patients with measurable (RECIST v1.1) ES-SCLC, ECOG performance status 0 or 1, who had not received prior systemic treatment for ES-SCLC were enrolled. Patients were randomized 1:1 to nivolumab 360 mg + CE every 21 days for 4 cycles followed by maintenance nivolumab 240 mg every 2 weeks until progression or up to 2 years (arm A) or CE every 21 days for 4 cycles followed by observation (arm B). Prophylactic cranial irradiation (PCI) was permitted at the investigator’s discretion. Investigator’s choice of cisplatin or carboplatin was allowed across both arms. The primary endpoint was PFS in eligible and treated patients. Secondary endpoints included OS, ORR, and safety. Adverse events (AEs) were graded per NCI-CTCAE v4.0.

Results: This study was activated in May 2018 and completed accrual in December 2018. 160 patients were enrolled. Baseline characteristics were well balanced between arms. In the ITT population (n = 160), nivolumab + CE significantly improved the PFS compared to CE with HR 0.65 (95% CI, 0.46, 0.91; p = 0.012); mPFS 5.5 versus 4.6 months, respectively. Secondary endpoint of OS was also improved with nivolumab + CE versus CE with HR 0.67 (95% CI, 0.46, 0.98; p = 0.038); mOS 11.3 versus 8.5 months. Among patients who initiated study therapy, nivolumab + CE significantly improved the PFS compared to CE with HR 0.68 (95% CI, 0.48, 1.00; p = 0.047); mPFS 5.5 versus 4.7 months, respectively; in this population, OS was also improved with nivolumab + CE versus CE with HR 0.73 (95% CI, 0.49, 1.11; p = 0.14); mOS 11.3 versus 9.3 months. The ORR was 52.29% versus 47.71%. The incidence of treatment-related grade 3/4 AEs was 77% versus 62% and AEs leading to discontinuation 6.21% versus 2.07%. Ten patients remain on maintenance nivolumab. Lethal adverse events independent of treatment were similar between the two arms (9 in arm A; 7 in arm B).

Conclusions: The addition of nivolumab to CE as 1L treatment for ES-SCLC significantly improved PFS and OS. No new safety signals were observed. Clinical trial information: NCT03382561

Subtitles:
Loading...

Download Slides
Oral Abstract Presentation
Selected by the 2020 Annual Meeting Scientific Program Committee
Type: Oral Abstract Presentation
Presenter: Ticiana Leal, MD
Presented: May 29, 2020
Abstract ref: 9000
Subtitles/Captions: